Literature DB >> 28074670

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.

Ricardo Jorge Dinis-Oliveira1,2,3.   

Abstract

Psilocybin and psilocin are controlled substances in many countries. These are the two main hallucinogenic compounds of the "magic mushrooms" and both act as agonists or partial agonists at 5-hydroxytryptamine (5-HT)2A subtype receptors. During the last few years, psilocybin and psilocin have gained therapeutic relevance but considerable physiological variability between individuals that can influence dose-response and toxicological profile has been reported. This review aims to discuss metabolism of psilocybin and psilocin, by presenting all major and minor psychoactive metabolites. Psilocybin is primarily a pro-drug that is dephosphorylated by alkaline phosphatase to active metabolite psilocin. This last is then further metabolized, psilocin-O-glucuronide being the main urinary metabolite with clinical and forensic relevance in diagnosis.

Entities:  

Keywords:  Psilocybin; metabolism; metabolomics; psilocin; toxicity; toxicokinetics

Mesh:

Substances:

Year:  2017        PMID: 28074670     DOI: 10.1080/03602532.2016.1278228

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  19 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.

Authors:  Ricardo Jorge Dinis-Oliveira; Carolina Lança Pereira; Diana Dias da Silva
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

Review 2.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

Review 3.  Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Authors:  Susan Ling; Felicia Ceban; Leanna M W Lui; Yena Lee; Kayla M Teopiz; Nelson B Rodrigues; Orly Lipsitz; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Kangguang Lin; Roger Ho; Joshua D Rosenblat; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2021-11-17       Impact factor: 5.749

4.  Optimization through a Box-Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis).

Authors:  Curro Polo-Castellano; José Á Álvarez; Miguel Palma; Gerardo F Barbero; Jesús Ayuso; Marta Ferreiro-González
Journal:  J Fungi (Basel)       Date:  2022-06-02

Review 5.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

6.  Horizontal gene cluster transfer increased hallucinogenic mushroom diversity.

Authors:  Hannah T Reynolds; Vinod Vijayakumar; Emile Gluck-Thaler; Hailee Brynn Korotkin; Patrick Brandon Matheny; Jason C Slot
Journal:  Evol Lett       Date:  2018-02-27

7.  Bis(4-acet-oxy-N,N-di-methyl-tryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug.

Authors:  Andrew R Chadeayne; James A Golen; David R Manke
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2019-05-31

Review 8.  Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms.

Authors:  Jiri Patocka; Ran Wu; Eugenie Nepovimova; Martin Valis; Wenda Wu; Kamil Kuca
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

Review 9.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03

10.  Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives.

Authors:  N Milne; P Thomsen; N Mølgaard Knudsen; P Rubaszka; M Kristensen; I Borodina
Journal:  Metab Eng       Date:  2020-03-26       Impact factor: 9.783

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.